BACKGROUND: Psychological morbidity has been proposed as a source of distress in cancer patients. This study aimed to: 1) determine the prevalence of diagnosable psychiatric illnesses, and 2) describe the mental health services received and predictors of service utilization in patients with advanced cancer. METHODS: This was a cross-sectional, multi-institutional study of 251 eligible patients with advanced cancer. Eligibility included: distant metastases, primary therapy failure, nonpaid caregiver, age > or =20 years, stamina for the interview, English or Spanish-speaking, and adequate cognitive ability. Trained interviewers administered the Structured Clinical Interview for the Diagnostic Statistical Manual IV (DSM-IV) modules for Major Depressive Disorder, Generalized Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder, and a detailed questionnaire regarding mental health service utilization. RESULTS: Overall, 12% met criteria for a major psychiatric condition and 28% had accessed a mental health intervention for a psychiatric illness since the cancer diagnosis. Seventeen percent had discussions with a mental health professional; 90% were willing to receive treatment for emotional problems. Mental health services were not accessed by 55% of patients with major psychiatric disorders. Cancer patients who had discussed psychological concerns with mental health staff (odds ratio [OR] = 19.2; 95% confidence interval [95% CI], 8.90-41.50) and non-Hispanic white patients (OR = 2.7; 95% CI, 1.01-7.43) were more likely to receive mental health services in adjusted analysis. CONCLUSIONS: Advanced cancer patients experience major psychiatric disorders at a prevalence similar to the general population, but affected individuals have a low rate of utilizing mental health services. Oncology providers can enhance utilization of mental health services, and potentially improve clinical outcomes, by discussing mental health concerns with their patients. Copyright 2005 American Cancer Society.
BACKGROUND: Psychological morbidity has been proposed as a source of distress in cancerpatients. This study aimed to: 1) determine the prevalence of diagnosable psychiatric illnesses, and 2) describe the mental health services received and predictors of service utilization in patients with advanced cancer. METHODS: This was a cross-sectional, multi-institutional study of 251 eligible patients with advanced cancer. Eligibility included: distant metastases, primary therapy failure, nonpaid caregiver, age > or =20 years, stamina for the interview, English or Spanish-speaking, and adequate cognitive ability. Trained interviewers administered the Structured Clinical Interview for the Diagnostic Statistical Manual IV (DSM-IV) modules for Major Depressive Disorder, Generalized Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder, and a detailed questionnaire regarding mental health service utilization. RESULTS: Overall, 12% met criteria for a major psychiatric condition and 28% had accessed a mental health intervention for a psychiatric illness since the cancer diagnosis. Seventeen percent had discussions with a mental health professional; 90% were willing to receive treatment for emotional problems. Mental health services were not accessed by 55% of patients with major psychiatric disorders. Cancerpatients who had discussed psychological concerns with mental health staff (odds ratio [OR] = 19.2; 95% confidence interval [95% CI], 8.90-41.50) and non-Hispanic white patients (OR = 2.7; 95% CI, 1.01-7.43) were more likely to receive mental health services in adjusted analysis. CONCLUSIONS: Advanced cancerpatients experience major psychiatric disorders at a prevalence similar to the general population, but affected individuals have a low rate of utilizing mental health services. Oncology providers can enhance utilization of mental health services, and potentially improve clinical outcomes, by discussing mental health concerns with their patients. Copyright 2005 American Cancer Society.
Authors: L A Ries; P A Wingo; D S Miller; H L Howe; H K Weir; H M Rosenberg; S W Vernon; K Cronin; B K Edwards Journal: Cancer Date: 2000-05-15 Impact factor: 6.860
Authors: W Breitbart; B Rosenfeld; H Pessin; M Kaim; J Funesti-Esch; M Galietta; C J Nelson; R Brescia Journal: JAMA Date: 2000-12-13 Impact factor: 56.272
Authors: S B Lansky; M A List; C A Herrmann; E G Ets-Hokin; T K DasGupta; G D Wilbanks; F R Hendrickson Journal: J Clin Oncol Date: 1985-11 Impact factor: 44.544
Authors: L R Derogatis; G R Morrow; J Fetting; D Penman; S Piasetsky; A M Schmale; M Henrichs; C L Carnicke Journal: JAMA Date: 1983-02-11 Impact factor: 56.272
Authors: Xiao-Cheng Wu; Pinki K Prasad; Ian Landry; Linda C Harlan; Helen M Parsons; Charles F Lynch; Ashley W Smith; Ann S Hamilton; Theresa H M Keegan Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-09-29 Impact factor: 4.254
Authors: Allison J Applebaum; Emma M Stein; Jennifer Lord-Bessen; Hayley Pessin; Barry Rosenfeld; William Breitbart Journal: Psychooncology Date: 2013-10-07 Impact factor: 3.894
Authors: Joanne M Shaw; Melanie A Price; Josephine M Clayton; Peter Grimison; Tim Shaw; Nicole Rankin; Phyllis N Butow Journal: Support Care Cancer Date: 2015-04-23 Impact factor: 3.603
Authors: Kelly M Trevino; Charlotte Healy; Peter Martin; Beverly Canin; Karl Pillemer; Jo Anne Sirey; M Cary Reid Journal: J Geriatr Oncol Date: 2018-09 Impact factor: 3.599
Authors: Catherine E Mosher; Courtney Johnson; Maura Dickler; Larry Norton; Mary Jane Massie; Katherine DuHamel Journal: Breast J Date: 2013-03-26 Impact factor: 2.431